Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Primary Sponsor
ANZUP
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Contact
enzarad.study@sydney.edu.au
Related Post
4 December, 2025
TROG Concept Development Workshop sows seeds for innovative new research
LATEST NEWS: 4 December 2025 TROG provided a kick-start
26 November, 2025
TROG Member Prof Paul Keall’s innovative research recognised in two Premier’s Awards
LATEST NEWS; 26 November 2025 Medical physics researcher and